Apr 21, 2017
Latest niche market research study on “Antibacterial Therapies Drug Development Pipeline Review, 2017 "published at Orbisresearch.com

Dallas, United States - April 21, 2017 /MarketersMedia/ —
The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.
There are over 1400 products in active development in the antibacterial drug market, with the majority of products being small molecules. Vaccines are also well established within the market, and accounts for approximately 25% of the pipeline.
Buy a report @ http://www.orbisresearch.com/contact/purchase/248270 .
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Scope
- Which companies are the most active within the pipeline for antibacterial drugs?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?
Get the DISCOUNT of this report @ http://www.orbisresearch.com/contacts/discount/248270 .
Currently, drugs for the prevention of bacterial infections are typically vaccines which help to train the body’s immune system to fight off bacterial infections caused by specific bacterial strains. However, several prophylactic monoclonal antibodies are now in the pipeline and may impact the market in the near future.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, such as penicillin, and protein synthesis inhibitors. However, bacterial resistance has reduced the efficacy of many of these drugs. As a result the pipeline includes a variety of new-generation protein synthesis inhibitors and beta-lactam/beta-lactamase inhibitor combination drugs, which are active against currently hard to treat bacterial strains.
The report provides comprehensive information on the pipeline development landscape for Pneumonia, Methicillin-resistant staphylococcus aureus (MRSA) and Tuberculosis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.
Browse the complete report @ http://www.orbisresearch.com/reports/index/antibacterial-therapies-drug-development-pipeline-review-2017 .
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Info:
Name: Hector Costello
Email: [email protected]
Organization: Orbis Research
Address: 4144N Central Expressway, Suite 600
Phone: +1 (214) 884-6817
Source URL: http://marketersmedia.com/pipeline-review-2017-antibacterial-therapies-drug-market-research-report/187971
For more information, please visit http://www.orbisresearch.com/reports/index/antibacterial-therapies-drug-development-pipeline-review-2017
Source: MarketersMedia
Release ID: 187971
The sports agent has fueled fresh speculation about his relationship with the Grammy-winning singer after an unexpected remark during an online challenge, nearly two years after the couple publicly confirmed their engagement.
The Hollywood star opens the doors to his normally private family life in a deeply personal new film, revealing his close bond with his eldest child while highlighting the challenges faced by young adults with disabilities.
Australia was promised a poet laureate to bust out some rhymes for the nation almost four years ago. So where are they?
After 12 gruelling weeks, the latest season of The Block has come to a dramatic climax, with five luxury homes going under the hammer.
The British actor has revisited his experience working alongside John Hurt in the acclaimed political thriller, reflecting on its unsettling relevance today and the remarkable permission filmmakers received to shoot in London's government district.
A young Perth classical singer didn’t let her vocal disorder slow her down as she entered the finals of a national singing competition, taking home two prizes including an international mentorship.
The Assassin, All’s Fair, Black Doves & The New Stanford Prison Experiment: Here’s what our Screen Queen Clare Rigden is watching this week on Aussie TV.
Dame Judy Dench says she has great hope for the future of theatre, so long as people keep going to shows and the production "promotes a conversation".
Tim McGraw has quashed a "rumour" that he performed at Taylor Swift and Travis Kelce's wedding, though he did attend as a guest.
Two previously unheard Ozzy Osbourne tracks are set to be released in conjunction with his upcoming biopic.
Martin Scorsese has claimed Seth Rogen "ruined" his planned Cleopatra film because of the Sony hack back in 2014.
Filming on The Batman Part II was reportedly paused after a cast member was run over by the Batmobile.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.